STOCKWATCH: Running the gamut of commotions from A to A
This article was originally published in Scrip
Executive Summary
As the third quarter earnings season got under way last week, bad news across the sector seemed to be focused on companies with names starting at the front of the alphabet, like Ariad, AMAG, Alimera Sciences and Amarin. But away from 'A', Johnson & Johnson's continuing good performance raised interesting questions not only for pharmaceutical firms, but also for their competitors in the devices or diagnostics sectors.